Clinical Trial Update: CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis [EARLY_Phase 1]

View source ↗

Summary

This update notes an early-phase Phase 1 trial of CD19/BCMA CAR-T cell therapy for refractory/relapsed lupus nephritis that is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis

Drugs mentioned

• CD19/BCMA CAR-T Cell Therapy

Snippet

Sponsor: He Huang | Conditions: Lupus Nephritis | EARLY_Phase 1 | Status: RECRUITING